An evaluation of current GERD therapy: A summary and comparison of effectiveness, adverse effects and costs of drugs, surgery and endoscopic therapy

Best Practice and Research: Clinical Gastroenterology

Volumn 18, Issue SUPPL., 2004, Pages 39-45

  Katelaris, Peter H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ADENOCARCINOMA; ARTICLE; BACTERIAL INFECTION; BEHAVIOR MODIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CAUCASIAN; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; ESOPHAGITIS; ESOPHAGUS CARCINOMA; ESOPHAGUS STRICTURE; GASTRITIS; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SURGERY; HEADACHE; HEALTH CARE COST; HUMAN; HYPERSENSITIVITY REACTION; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; LIFESTYLE; MALABSORPTION; MORBIDITY; NAUSEA; PATIENT SELECTION; POPULATION RESEARCH; QUALITATIVE ANALYSIS; QUALITY OF LIFE; RISK ASSESSMENT; STOMACH FUNDOPLICATION; SYMPTOMATOLOGY;

ANTACIDS; COST-BENEFIT ANALYSIS; DRUG COSTS; ENDOSCOPY, GASTROINTESTINAL; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; PROTON PUMPS;

EID: 10644227632     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2004.06.011     Document Type: Article

References (22)

1. N. Chiba C.J. De Gara J.M. Wilkinson R.H. Hunt Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis Gastroenterology 112 1997 1798-1810
2. P. Katelaris R. Holloway N. Talley et al. Digestive Health Foundation of the Gastroenterological Society of Australia. Gastro-oesophageal reflux disease in adults: Guidelines for clinicians J Gastroenterol Hepatol 17 2002 825-833
3. N.J. Talley K. Lauritsen H. Tunturi-Hihnala et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on-demand' therapy for 6 months Aliment Pharmacol Ther 15 2001 347-354
4. J. Moessner H. Koop H. Porst et al. One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis Aliment Pharmacol Ther 11 1997 1087-1092
5. E.C. Klinkenberg-Knol F. Nelis J. Dent et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa Gastroenterology 118 2000 661-669
6. E.J. Kuipers L. Lundell E.C. Klinkenberg-Knol et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication N Engl J Med 334 1996 1018-1022
7. P. Moayyedi C. Wason R. Peacock et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression Helicobacter 5 2000 206-214
8. P. Malfertheiner F. Megraud C. O'Morain et al. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report Aliment Pharmacol Ther 16 2002 167-180
9. J.J. Ofman G.H. Dorn M.B. Fennerty R. Fass The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease Aliment Pharmacol Ther 16 2002 261-273
10. L.B. Gerson A.S. Robbins A. Garber et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease Am J Gastroenterol 95 2000 395-407
11. R.A. Harris M. Kuppermann J.E. Richter Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: A cost-effectiveness analysis Am J Gastroenterol 92 1997 2179-2187
12. R. Goeree B.J. O'Brien G. Blackhouse et al. Cost-effectiveness and cost-utility of long-term management strategies for heartburn Value Health 5 2002 312-328
13. J.H. You A.C. Lee S.C. Wong F.K. Chan Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: A cost-effectiveness analysis Aliment Pharmacol Ther 17 2003 785-792
14. D.C. Gotley B.M. Smithers M. Rhodes et al. Laparoscopic Nissen fundoplication-200 consecutive cases Gut 38 1996 487-491
15. M. Bloomston W. Nields A.S. Rosemurgy Symptoms and antireflux medication use following laparoscopic Nissen fundoplication: Outcome at 1 and 4 years JSLS 7 2003 211-218
16. S.J. Spechler E. Lee D. Ahnen et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial JAMA 285 2001 2331-2338
17. N. Vakil M. Shaw R. Kirby Clinical effectiveness of laparoscopic fundoplication in a U.S. community Am J Med 114 2003 1-5
18. G. Perdikis R.A. Hinder R.J. Lund et al. Laparoscopic Nissen fundoplication: Where do we stand? Surg Laparosc Endosc 7 1997 17-21
19. H.R. Koelz A.L. Blum I.M. Modlin Costs of GERD: Facts and fiction Gastroenterology 125 2003 981-982
20. A. Sonnenberg Motion-Laparoscopic Nissen fundoplication is more cost-effective than oral PPI administration: Arguments against the motion Can J Gastroenterol 16 2002 627-631
21. P.J. Kahrilas Radiofrequency energy treatment of GERD Gastroenterology 125 2003 970-973
22. W.J. Hogan R. Shaker A critical review of endoscopic therapy for gastroesophageal reflux disease Am J Med 115 Suppl 3A 2003 201S-210S